Management of Adverse Events During Rucaparib Treatment for Relapsed Ovarian Cancer: A Review of Published Studies and Practical Guidance

The poly(ADP-ribose) polymerase inhibitor rucaparib is approved as monotherapy in the treatment and maintenance settings for women with relapsed ovarian cancer in the European Union and the United States. We review the safety profile of rucaparib in both settings and provide recommendations for the...

Descripción completa

Detalles Bibliográficos
Autores principales: Lorusso, Domenica, García-Donas, Jesús, Sehouli, Jalid, Joly, Florence
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Therapy in Practice
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7283207/
https://www.ncbi.nlm.nih.gov/pubmed/32495160
http://dx.doi.org/10.1007/s11523-020-00715-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7283207/
https://www.ncbi.nlm.nih.gov/pubmed/32495160
http://dx.doi.org/10.1007/s11523-020-00715-z

Ejemplares similares